Inactive Instrument

Neuralstem, Inc. Stock Nyse

US64127R3021

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 16	Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	MT
Apr. 16	Palisade Bio Shows Bioactivation of PALI-2108 in Study; Shares Rise	MT

Latest news about Neuralstem, Inc.

Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	Apr. 16	MT
Palisade Bio Shows Bioactivation of PALI-2108 in Study; Shares Rise	Apr. 16	MT
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients? Stool	Apr. 16	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Palisade Bio, Inc. Announces Resignation of Mary Ann Gray as Member of the Board	Mar. 06	CI
Palisade Bio Names Donald Williams as Chairman	Feb. 13	MT
Palisade Bio, Inc. Announces Advisory Board Appointments	Feb. 08	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 29	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	Jan. 29	MT
Top Midday Gainers	Jan. 29	MT
Palisade Bio's Shares Climb Following Preclinical Data on Ulcerative Colitis Drug Candidate	Jan. 29	MT
Palisade Bio Says Giiant Pharma Receives Second Milestone Payment for PALI-2108 Development	Dec. 28	MT
North American Morning Briefing : Stocks Futures -2-	Nov. 20	DJ
Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $1.50	Nov. 17	MT

More news

Analyst Recommendations on Neuralstem, Inc.

Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $1.50	Nov. 17	MT
Ladenburg Thalmann Adjusts Price Target on Palisade Bio to $16 From $25, Maintains Buy Rating	23-05-16	MT
Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $5	23-03-30	MT
Ladenburg Lowers Palisade Bio's Price Target to $1.50 From $5, Maintains Buy Rating	22-08-23	MT
Maxim Group Downgrades Palisade Bio to Hold From Buy	22-08-19	MT

More recommendations

Press releases Neuralstem, Inc.

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 in Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients Stool	Apr. 17	AQ
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool	Apr. 16	AQ
Palisade Bio to Participate in the Virtual Investor Lunch Break Event	Apr. 11	AQ
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™	Apr. 10	AQ
Palisade Bio Announces 1-for-15 Reverse Stock Split	Apr. 03	AQ

More press releases

News in other languages on Neuralstem, Inc.

MÄRKTE USA/Fester - Neue Rekordhochs dank sinkender Anleihezinsen	Jan. 29
LATE BRIEFING - Unternehmen und Märkte	Jan. 29
MÄRKTE USA/Kaum verändert - Vor Fed-Entscheid dominiert Zurückhaltung	Jan. 29
MÄRKTE USA/Wall Street startet wenig verändert in Fed-Woche	Jan. 29
MÄRKTE USA/Wall Street wenig verändert erwartet	Jan. 29

More news

Managers and Directors - Neuralstem, Inc.

Managers	Age	Since
Nicholas McCoy	-	-
Ryker Willie	-	-
Charles C. Wells	73	-

Members of the board	Title	Age	Since
Donald Williams		65	-
J. D. Finley		66	-
Bin Xian Wei BRD	Director/Board Member	54	19-02-04

More insiders

Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.

Sector

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Sales 2024 *	-	Sales 2025 *	-	Capitalization	4.32M
Net income 2024 *	-12M	Net income 2025 *	-15M	EV / Sales 2024 *	-
Net cash position 2024 *	-	Net cash position 2025 *	-	EV / Sales 2025 *	-
P/E ratio 2024 *	-0.35 x	P/E ratio 2025 *	-0.46 x	Employees	-
Yield 2024 *	-	Yield 2025 *	-	Free-Float	0%